>
>
Hyperlipidemia Drugs Market – By Type (Familial, Acquired), Drug Type (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors), Route of Administration (Oral, Parenteral), Distribution Channel- Global Forecast 2024 – 2032
Download Free PDF

Hyperlipidemia Drugs Market
Get a free sample of this reportGet a free sample of this report Hyperlipidemia Drugs Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2023
Companies covered: 16
Tables & Figures: 284
Countries covered: 23
Pages: 210
Download Free PDF
Hyperlipidemia Drugs Market Size
Hyperlipidemia Drugs Market size was valued at around USD 21.6 billion in 2023 and is estimated to grow at 3.2% CAGR from 2024 to 2032. Hyperlipidemia drugs are medications used to treat hyperlipidemia, a condition characterized by abnormally high levels of lipid and fats in the blood, such as cholesterol and triglycerides. These drugs aim to lower lipid levels to reduce the risk of cardiovascular diseases, including heart attack and stroke.
The rising prevalence of cardiovascular diseases is a significant driving factor for the market. For instance, according to a study published by National Library of Medicine in January 2024, coronary artery disease (CAD) accounts for approximately 6,10,000 deaths annually (estimated 1 in 4 deaths) and is the leading cause of mortality in the U.S. Also, it is third leading cause of mortality worldwide and is associated with 17.8 million deaths annually. This underscores the critical need for effective hyperlipidemia drugs to manage lipid levels and reduce the risk of cardiovascular events.
Furthermore, rising prevalence of hyperlipidemia, advancements in drug development, and rising geriatric population are also among the key factors promoting the growth of the market.
Hyperlipidemia Drugs Market Trends
Advancements in drug development within the market have revolutionized the approach to manage elevated lipid levels and associated cardiovascular risks. The introduction of innovative therapies such as PCSK9 inhibitors, gene therapy, and combination treatments has significantly enhanced the efficacy and convenience of hyperlipidemia management.
Hyperlipidemia Drugs Market Analysis
Based on type, the market is segmented into familial and acquired. The acquired segment of the market is forecasted to reach USD 18.5 billion by 2032.
Based on drug class, the hyperlipidemia drugs market is bifurcated into statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, PCSK9 inhibitors, combination, and other drug classess. The statins segment accounted for USD 6.4 billion in 2023.
Based on route of administration, the hyperlipidemia drugs market is segmented into oral and parenteral. The oral segment of the market is forecasted to reach USD 19.4 billion by 2032.
Based on distribution channel, the hyperlipidemia drugs market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment accounted for USD 7.9 billion in 2023.
The growth of the hyperlipidemia drugs market in the U.S. is projected to reach USD 10.5 billion by 2032.
The hyperlipidemia drugs market in the UK is expected to experience significant growth from 2024 to 2032.
The hyperlipidemia drugs market in Japan is anticipated to witness lucrative growth between 2024 and 2032.
The hyperlipidemia drugs market in Saudi Arabia is expected to experience significant growth from 2024 to 2032.
Hyperlipidemia Drugs Market Share
The hyperlipidemia drugs sector is highly competitive, featuring a mix of major global companies and smaller to medium-sized firms vying for market share. A pivotal aspect of market strategy is the continual introduction of innovative products leveraging diverse technologies. Prominent industry players command considerable influence in this dynamic landscape, often driving advancements through substantial investments in research and development. Stringent regulatory requirements for the approval of hyperlipidemia drugs and the need for high initial capital investments create hurdles for new entrants. Consequently, smaller players often focus on specific therapies to compete with established companies.
Hyperlipidemia Drugs Market Companies
Some of the eminent market participants operating in the hyperlipidemia drugs industry include:
Hyperlipidemia Drugs Industry News:
The hyperlipidemia drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:
Click here to Buy Section of this Report
Market, By Type
Market, By Drug Class
Market, By Route of Administration
Market, By Distribution Channel
The above information is provided for the following regions and countries: